Trial Profile
Investigation of the Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 28 Jan 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 07 Nov 2006 Status change
- 03 Oct 2006 Status change